Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Author:

Stalman Eileen W.ORCID,Wieske Luuk,Keijser Jim B.D.,van Dam Koos P.J.,Kummer Laura Y.L.,Wilbrink Maarten F.,van Kempen Zoé L.E.,Killestein Joep,Volkers Adriaan G.,Tas Sander W.,Boekel Laura,Wolbink Gerrit J.,van der Kooi Anneke J.,Raaphorst Joost,Löwenberg Mark,Takkenberg R. Bart,D’Haens Geert R.A.M.,Spuls Phyllis I.,Bekkenk Marcel W.,Musters Annelie H.,Post Nicoline F.,Bosma Angela L.,Hilhorst Marc L.,Vegting Yosta,Bemelman Frederique J.,Voskuyl Alexandre E.,Broens Bo,Parra Sanchez Agner,van Els Cécile A.C. M.,de Wit Jelle,Rutgers Abraham,de Leeuw Karina,Horváth Barbara,Verschuuren Jan J.G.M.,Ruiter Annabel M.,van Ouwerkerk Lotte,van der Woude Diane,Allaart Renée C.F.,Onno Teng Y.K.,van Paassen Pieter,Busch Matthias H.,Brusse Esther,van Doorn Pieter A.,Baars Adája E.,Hijnen Dirkjan,Schreurs Corine R.G.,van der Pol W. Ludo,Goedee H. Stephan,Steenhuis Maurice,Keijzer Sofie,Cristianawati Olvi,Brinke Anja ten,Verstegen Niels J.M.,Zwinderman Koos A.H.,van Ham S. Marieke,Rispens Theo,Welkers Matthijs R.,Jonges Marcel,Eftimov Filip,Kuijpers Taco W.

Funder

ZonMw

Publisher

Elsevier BV

Reference32 articles.

1. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of delta variant (B.1.617.2), the Netherlands, August to September 2021;de Gier;Euro Surveill,2021

2. Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance;Chen;J Chem Inf Model,2022

3. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease;Haberman;Ann Rheum Dis,2021

4. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: to wait and repopulate?;van Kempen;Mult Scler Relat Disord,2022

5. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study;Wieske;Lancet Rheumatol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3